- Report
- March 2025
- 276 Pages
Global
From €5324EUR$5,600USD£4,472GBP
- Report
- September 2024
- 143 Pages
Global
From €2851EUR$2,999USD£2,395GBP
- Report
- June 2024
- 200 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Report
- May 2024
- 170 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Clinical Trials
- December 2024
- 80 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Report
- December 2024
- 43 Pages
Global
From €3798EUR$3,995USD£3,191GBP
- Report
- March 2024
- 221 Pages
Global
From €3422EUR$3,600USD£2,875GBP
- Report
- March 2024
- 121 Pages
Europe
From €1426EUR$1,500USD£1,198GBP
- Report
- March 2024
- 122 Pages
Asia Pacific
From €1426EUR$1,500USD£1,198GBP
- Report
- March 2024
- 112 Pages
North America
From €1426EUR$1,500USD£1,198GBP
- Report
- March 2024
- 121 Pages
Africa, Middle East
From €1426EUR$1,500USD£1,198GBP
- Report
- October 2022
- 270 Pages
Global
From €3565EUR$3,750USD£2,995GBP
- Report
- February 2024
- 250 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- September 2022
- 141 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- April 2023
- 160 Pages
Global
From €4705EUR$4,949USD£3,952GBP
- Report
- May 2023
- 160 Pages
Global
From €4705EUR$4,949USD£3,952GBP
- Report
- October 2023
- 145 Pages
Global
From €2995EUR$3,150USD£2,516GBP
- Report
- May 2023
- 97 Pages
Global
From €3323EUR$3,495USD£2,791GBP
- Report
- August 2022
- 465 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- August 2022
United States
From €1844EUR$1,940USD£1,549GBP

Psoriatic Arthritis Drug is a type of drug used to treat psoriatic arthritis, a type of immune disorder. It is a chronic, inflammatory condition that affects the joints and skin. Psoriatic Arthritis Drug works by targeting the underlying cause of the disease, which is an overactive immune system. It helps to reduce inflammation and pain, and can also slow down the progression of the disease. Commonly used Psoriatic Arthritis Drugs include biologics, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and disease-modifying antirheumatic drugs (DMARDs).
The Psoriatic Arthritis Drug market is a rapidly growing segment of the Immune Disorders Drugs market. It is driven by the increasing prevalence of psoriatic arthritis, as well as the development of new and more effective treatments. The market is expected to continue to grow in the coming years, as more treatments become available and the demand for them increases.
Some of the major companies in the Psoriatic Arthritis Drug market include AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and Roche. Show Less Read more